Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Money Too Tight To Mention At Motif After Iclaprim 'No' From FDA

Executive Summary

Hit with a complete response letter from the US FDA for its antibiotic to treat ABSSSI, Motif needs to raise funds and fast to stay afloat and prepare a meeting package to discuss the next steps for iclaprim with the agency.

Advertisement

Related Content

Keeping Track: Rebuff Of Iclaprim Creates Early Pileup Of CRLs For Novel Drugs
Motif Bio Poised For Filings As Iclaprim Succeeds Again In Phase III
Motif A Step Closer To Succeeding With Iclaprim After Phase III Success
US panel knocks efficacy of Arpida's iclaprim for skin infections

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124691

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel